Paulina Rybakowska
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Paulina Rybakowska has a total of 87 co-authors. Here are the top co-authors by number of shared publications:
- Concepción Marañón
Pfizer-University of Granada-Junta de Andalucía Centre for Genomics and Oncological Research (GENYO), Pfizer/University of Granada/Andalusian Regional Government, PTS Granada, Avda. de la Ilustración 114, Granada 18016, Spain
5 shared publications Astrid Rasmussen
Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA
2 shared publicationsHarini Bagavant
Division of Nephrology, University of Virginia, Charlottesville, Virginia, USA Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA
2 shared publicationsKiely Grundahl
Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA
2 shared publicationsLida Radfar
Department of Oral Diagnosis and Radiology, University of Oklahoma College of Dentistry, Oklahoma City, Oklahoma, USA
2 shared publicationsMarta E. Alarcón-Riquelme
Pfizer-University of Granada-Junta de Andalucía Centre for Genomics and Oncological Research (GENYO), PTS, Granada, Spain. Institute for Environmental Medicine, Karolinska Institutet, Stockholm, Sweden
2 shared publications
Latest Publications
- Open Access
- 17 March 2026
- Published by Elsevier in Journal of Infection
- Vol. 92 (5) , 106731
Persistent T cell phenotypic alterations and early innate immune dysregulation as potential biomarkers of Long COVID
- 17 March 2026
- Published by Elsevier in Journal of Infection
- Vol. 92 (5) , 106731
Open AccessPersistent T cell phenotypic alterations and early innate immune dysregulation as potential biomarkers of Long COVID
- Open Access
Systemic autoimmune disease patients’ blood immunome reveals specificities and commonalities among different diagnostic entities
1 Background: Systemic autoimmune diseases (SADs) are characterized by internal heterogeneity, overlapping clinical symptoms, and shared molecular pathways. Therefore, they are difficult to diagnose and new tools allowing precise diagnosis are needed. Molecular-based reclassification studies enable to find patterns in a diagnosis-independent way. Objective: To evaluate the possibility of using high-content immunophenotyping for detecting patient subgroups in the context of precise treatment. Methods: Whole blood high-content immunophenotyping of 101 patients with 7 systemic autoimmune diseases and 22 controls was performed using 36-plex mass cytometry panel. Patients were compared across diagnostic entities and re-classified using Monte Carlo reference-based consensus clustering. Levels of 45-plex multiplexed cytokine were measured and used for cluster characterization. Results: Differential analysis by diagnosis did not reveal any disease-specific pattern in the cellular compositions and phenotypes but rather their relative similarities. Accordingly, patients were classified into phenotypically distinct groups composed of different diagnostic entities sharing common immunophenotypes and cytokine signatures. These features were mainly based on granulocyte activation and CD38 expression in discrete lymphocyte populations and were related to Th17 or IFN-dependent cytokines. Conclusions: Our data indicate that specific individuals could potentially benefit from the same line of treatment independently of their diagnosis and emphasize the possibility of using immunophenotyping as a stratification tool in precision rheumatology. 2 Graphical Key messages: Whole blood immmunophenotyping could be used to stratify systemic autoimmune patients, thus it is a useful tool in precision medicine. Patients’ groups could benefit from the same line of treatment.
Open AccessSystemic autoimmune disease patients’ blood immunome reveals specificities and commonalities among different diagnostic entities
1 Background: Systemic autoimmune diseases (SADs) are characterized by internal heterogeneity, overlapping clinical symptoms, and shared molecular pathways. Therefore, they are difficult to diagnose and new tools allowing precise diagnosis are needed. Molecular-based reclassification studies enable to find patterns in a diagnosis-independent way. Objective: To evaluate the possibility of using high-content immunophenotyping for detecting patient subgroups in the context of precise treatment. Methods: Whole blood high-content immunophenotyping of 101 patients with 7 systemic autoimmune diseases and 22 controls was performed using 36-plex mass cytometry panel. Patients were compared across diagnostic entities and re-classified using Monte Carlo reference-based consensus clustering. Levels of 45-plex multiplexed cytokine were measured and used for cluster characterization. Results: Differential analysis by diagnosis did not reveal any disease-specific pattern in the cellular compositions and phenotypes but rather their relative similarities. Accordingly, patients were classified into phenotypically distinct groups composed of different diagnostic entities sharing common immunophenotypes and cytokine signatures. These features were mainly based on granulocyte activation and CD38 expression in discrete lymphocyte populations and were related to Th17 or IFN-dependent cytokines. Conclusions: Our data indicate that specific individuals could potentially benefit from the same line of treatment independently of their diagnosis and emphasize the possibility of using immunophenotyping as a stratification tool in precision rheumatology. 2 Graphical Key messages: Whole blood immmunophenotyping could be used to stratify systemic autoimmune patients, thus it is a useful tool in precision medicine. Patients’ groups could benefit from the same line of treatment.
- Open Access
- 31 October 2022
- Published by Elsevier in STAR Protocols
- Vol. 3 (4) , 101697
Protocol for large scale whole blood immune monitoring by mass cytometry and Cyto Quality Pipeline
- 31 October 2022
- Published by Elsevier in STAR Protocols
- Vol. 3 (4) , 101697
Open AccessProtocol for large scale whole blood immune monitoring by mass cytometry and Cyto Quality Pipeline
- Top Cited PapersOpen Access
- 22 September 2021
- Published by Wiley in Cytometry Part A
- Vol. 101 (4) , 325-338
PeacoQC: Peak‐based selection of high quality cytometry data
In cytometry analysis, a large number of markers is measured for thousands or millions of cells, resulting in high‐dimensional datasets. During the measurement of these samples, erroneous events can occur such as clogs, speed changes, slow uptake of the sample etc., which can influence the downstream analysis and can even lead to false discoveries. As these issues can be difficult to detect manually, an automated approach is recommended. In order to filter these erroneous events out, we created a novel quality control algorithm, Peak Extraction And Cleaning Oriented Quality Control (PeacoQC), that allows for automated cleaning of cytometry data. The algorithm will determine density peaks per channel on which it will remove low quality events based on their position in the isolation tree and on their mean absolute deviation distance to these density peaks. To evaluate PeacoQC's cleaning capability, it was compared to three other existing quality control algorithms (flowAI, flowClean and flowCut) on a wide variety of datasets. In comparison to the other algorithms, PeacoQC was able to filter out all different types of anomalies in flow, mass and spectral cytometry data, while the other methods struggled with at least one type. In the quantitative comparison, PeacoQC obtained the highest median balanced accuracy and a similar running time compared to the other algorithms while having a better scalability for large files. To ensure that the parameters chosen in the PeacoQC algorithm are robust, the cleaning tool was run on 16 public datasets. After inspection, only one sample was found where the parameters should be further optimized. The other 15 datasets were analyzed correctly indicating a robust parameter choice. Overall, we present a fast and accurate quality control algorithm that outperforms existing tools and ensures high‐quality data that can be used for further downstream analysis. An R implementation is available.
- 22 September 2021
- Published by Wiley in Cytometry Part A
- Vol. 101 (4) , 325-338
Top Cited PapersOpen AccessPeacoQC: Peak‐based selection of high quality cytometry data
In cytometry analysis, a large number of markers is measured for thousands or millions of cells, resulting in high‐dimensional datasets. During the measurement of these samples, erroneous events can occur such as clogs, speed changes, slow uptake of the sample etc., which can influence the downstream analysis and can even lead to false discoveries. As these issues can be difficult to detect manually, an automated approach is recommended. In order to filter these erroneous events out, we created a novel quality control algorithm, Peak Extraction And Cleaning Oriented Quality Control (PeacoQC), that allows for automated cleaning of cytometry data. The algorithm will determine density peaks per channel on which it will remove low quality events based on their position in the isolation tree and on their mean absolute deviation distance to these density peaks. To evaluate PeacoQC's cleaning capability, it was compared to three other existing quality control algorithms (flowAI, flowClean and flowCut) on a wide variety of datasets. In comparison to the other algorithms, PeacoQC was able to filter out all different types of anomalies in flow, mass and spectral cytometry data, while the other methods struggled with at least one type. In the quantitative comparison, PeacoQC obtained the highest median balanced accuracy and a similar running time compared to the other algorithms while having a better scalability for large files. To ensure that the parameters chosen in the PeacoQC algorithm are robust, the cleaning tool was run on 16 public datasets. After inspection, only one sample was found where the parameters should be further optimized. The other 15 datasets were analyzed correctly indicating a robust parameter choice. Overall, we present a fast and accurate quality control algorithm that outperforms existing tools and ensures high‐quality data that can be used for further downstream analysis. An R implementation is available.
- 18 October 2020
- Published by Wiley in Cytometry Part A
- Vol. 99 (5) , 524-537
Stabilization of Human Whole Blood Samples for Multicenter and Retrospective Immunophenotyping Studies
Whole blood is often collected for large‐scale immune monitoring studies to track changes in cell frequencies and responses using flow (FC) or mass cytometry (MC). In order to preserve sample composition and phenotype, blood samples should be analyzed within 24 h after bleeding, restricting the recruitment, analysis protocols, as well as biobanking. Herein, we have evaluated two whole blood preservation protocols that allow rapid sample processing and long‐term stability. Two fixation buffers were used, Phosphoflow Fix and Lyse (BD) and Proteomic Stabilizer (PROT) to fix and freeze whole blood samples for up to 6 months. After analysis by an 8‐plex panel by FC and a 26‐plex panel by MC, manual gating of circulating leukocyte populations and cytokines was performed. Additionally, we tested the stability of a single sample over a 13‐months period using 45 consecutive aliquots and a 34‐plex panel by MC. We observed high correlation and low bias toward any cell population when comparing fresh and 6 months frozen blood with FC and MC. This correlation was confirmed by hierarchical clustering. Low coefficients of variation (CV) across studied time points indicate good sample preservation for up to 6 months. Cytokine detection stability was confirmed by low CVs, with some differences between fresh and fixed conditions. Thirteen months regular follow‐up of PROT samples showed remarkable sample stability. Whole blood can be preserved for phenotyping and cytokine‐response studies provided the careful selection of a compatible antibody panel. However, possible changes in cell morphology, differences in antibody affinity, and changes in cytokine‐positive cell frequencies when compared to fresh blood should be considered. Our setting constitutes a valuable tool for multicentric and retrospective studies. © 2020 International Society for Advancement of Cytometry
- 18 October 2020
- Published by Wiley in Cytometry Part A
- Vol. 99 (5) , 524-537
Stabilization of Human Whole Blood Samples for Multicenter and Retrospective Immunophenotyping Studies
Whole blood is often collected for large‐scale immune monitoring studies to track changes in cell frequencies and responses using flow (FC) or mass cytometry (MC). In order to preserve sample composition and phenotype, blood samples should be analyzed within 24 h after bleeding, restricting the recruitment, analysis protocols, as well as biobanking. Herein, we have evaluated two whole blood preservation protocols that allow rapid sample processing and long‐term stability. Two fixation buffers were used, Phosphoflow Fix and Lyse (BD) and Proteomic Stabilizer (PROT) to fix and freeze whole blood samples for up to 6 months. After analysis by an 8‐plex panel by FC and a 26‐plex panel by MC, manual gating of circulating leukocyte populations and cytokines was performed. Additionally, we tested the stability of a single sample over a 13‐months period using 45 consecutive aliquots and a 34‐plex panel by MC. We observed high correlation and low bias toward any cell population when comparing fresh and 6 months frozen blood with FC and MC. This correlation was confirmed by hierarchical clustering. Low coefficients of variation (CV) across studied time points indicate good sample preservation for up to 6 months. Cytokine detection stability was confirmed by low CVs, with some differences between fresh and fixed conditions. Thirteen months regular follow‐up of PROT samples showed remarkable sample stability. Whole blood can be preserved for phenotyping and cytokine‐response studies provided the careful selection of a compatible antibody panel. However, possible changes in cell morphology, differences in antibody affinity, and changes in cytokine‐positive cell frequencies when compared to fresh blood should be considered. Our setting constitutes a valuable tool for multicentric and retrospective studies. © 2020 International Society for Advancement of Cytometry
- 1 March 2016
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 75 (3) , 617-622
Interaction between innate immunity and Ro52-induced antibody causes Sjögren's syndrome-like disorder in mice
Objectives Autoantibodies reactive with Ro52 are often found in sera of patients with Sjögren's syndrome (SS). This study was undertaken to investigate the role of Ro52-induced immune responses in pathogenesis of SS. Methods New Zealand Mixed (NZM) 2758 mice were immunised with Ro52 in alum adjuvant. Control mice were immunised either with maltose-binding protein or injected with alum alone. Mice were monitored for anti-Ro52 antibody, sialoadenitis and pilocarpine-induced salivation. Antibody binding to salivary gland (SG) cells was analysed in vivo and in vitro by immunofluorescence. Sera from immunised mice were passively transferred into untreated or alum injected NZM2758 mice. Results By day 30 post-immunisation, Ro52 immunised mice generated immunoprecipitating anti-Ro52 antibodies and they had the maximum drop in saliva production. Both Ro52 immunised and control mice showed evidence of mild sialoadenitis. However, only Ro52 immunised mice had antibody deposition in their SG. Passive transfer of Ro52-immune sera induced SG dysfunction in recipient mice, only if the recipients were primed with alum. In vitro, antibodies from Ro52-immune sera were internalised by a SG cell line and this uptake was inhibited by cytochalasin D treatment. Conclusions Our data show for the first time that antibodies induced by Ro52 are capable of inducing SG dysfunction, and that this phenomenon is dependent on the activation of innate immunity. The mouse model described in this study implies that autoantibody deposition in the SG might be an important step in the induction of xerostomia and pathogenesis of SS.
- 1 March 2016
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 75 (3) , 617-622
Interaction between innate immunity and Ro52-induced antibody causes Sjögren's syndrome-like disorder in mice
Objectives Autoantibodies reactive with Ro52 are often found in sera of patients with Sjögren's syndrome (SS). This study was undertaken to investigate the role of Ro52-induced immune responses in pathogenesis of SS. Methods New Zealand Mixed (NZM) 2758 mice were immunised with Ro52 in alum adjuvant. Control mice were immunised either with maltose-binding protein or injected with alum alone. Mice were monitored for anti-Ro52 antibody, sialoadenitis and pilocarpine-induced salivation. Antibody binding to salivary gland (SG) cells was analysed in vivo and in vitro by immunofluorescence. Sera from immunised mice were passively transferred into untreated or alum injected NZM2758 mice. Results By day 30 post-immunisation, Ro52 immunised mice generated immunoprecipitating anti-Ro52 antibodies and they had the maximum drop in saliva production. Both Ro52 immunised and control mice showed evidence of mild sialoadenitis. However, only Ro52 immunised mice had antibody deposition in their SG. Passive transfer of Ro52-immune sera induced SG dysfunction in recipient mice, only if the recipients were primed with alum. In vitro, antibodies from Ro52-immune sera were internalised by a SG cell line and this uptake was inhibited by cytochalasin D treatment. Conclusions Our data show for the first time that antibodies induced by Ro52 are capable of inducing SG dysfunction, and that this phenomenon is dependent on the activation of innate immunity. The mouse model described in this study implies that autoantibody deposition in the SG might be an important step in the induction of xerostomia and pathogenesis of SS.
- Open Access
- 4 December 2015
- Published by Wiley in Arthritis & Rheumatology
- Vol. 68 (3) , 724-729
Brief Report: Patients With Primary Sjögren's Syndrome Who Are Positive for Autoantibodies to Tripartite Motif–Containing Protein 38 Show Greater Disease Severity
Objective: Autoantibodies reactive with Ro52 (tripartite motif−containing protein 21 [TRIM21]) are detected in 70% of patients with primary Sjögren's syndrome (SS). TRIM21 belongs to a 34‐member C‐IV family of TRIM proteins. Although autoantibodies against other TRIM proteins within the C‐IV family have been detected in the sera of patients with primary SS, their clinical relevance remains unclear. This study was undertaken to investigate the frequency of anti‐TRIM38 in patients with primary SS and evaluate its association with various clinical measures of the disease.Methods: Serum samples from patients with primary SS (n = 235) and controls (n = 50) were analyzed for reactivity with in vitro−transcribed and −translated 35S‐methionine−labeled TRIM38 protein. The associations of anti‐TRIM38 with various laboratory and clinical measures of primary SS were evaluated. Reactivity of anti‐TRIM38 with different structural domains of TRIM38 was analyzed. Affinity‐purified anti‐TRIM38 antibodies were used to immunoprecipitate TRIM21.Results: TRIM38‐reactive autoantibodies were detected in the sera of 24 of the 235 patients with primary SS and 2 of the 50 controls. Anti‐TRIM38 positivity was significantly associated with the presence of anti‐Ro60, anti‐Ro52, anti‐La, rheumatoid factor, and hypergammaglobulinemia. Clinically, anti‐TRIM38 was associated with significantly higher ocular surface staining scores, lower Schirmer's test scores, and minor labial salivary gland biopsy focus scores of ≥3.0. Anti‐TRIM38 antibodies mainly recognized the cortactin‐binding protein 2 (CortBP‐2; amino acids 128–238) and the B30.2/SPRY (amino acids 268–465) domains on TRIM38. Affinity‐purified antibodies to TRIM38–CortBP‐2 and TRIM38–B30.2/SPRY domains reacted with TRIM21.Conclusion: Our data demonstrate that anti‐TRIM38 specificity arising in a subset of patients with primary SS is associated with increased severity of the disease.
- 4 December 2015
- Published by Wiley in Arthritis & Rheumatology
- Vol. 68 (3) , 724-729
Open AccessBrief Report: Patients With Primary Sjögren's Syndrome Who Are Positive for Autoantibodies to Tripartite Motif–Containing Protein 38 Show Greater Disease Severity
Objective: Autoantibodies reactive with Ro52 (tripartite motif−containing protein 21 [TRIM21]) are detected in 70% of patients with primary Sjögren's syndrome (SS). TRIM21 belongs to a 34‐member C‐IV family of TRIM proteins. Although autoantibodies against other TRIM proteins within the C‐IV family have been detected in the sera of patients with primary SS, their clinical relevance remains unclear. This study was undertaken to investigate the frequency of anti‐TRIM38 in patients with primary SS and evaluate its association with various clinical measures of the disease.Methods: Serum samples from patients with primary SS (n = 235) and controls (n = 50) were analyzed for reactivity with in vitro−transcribed and −translated 35S‐methionine−labeled TRIM38 protein. The associations of anti‐TRIM38 with various laboratory and clinical measures of primary SS were evaluated. Reactivity of anti‐TRIM38 with different structural domains of TRIM38 was analyzed. Affinity‐purified anti‐TRIM38 antibodies were used to immunoprecipitate TRIM21.Results: TRIM38‐reactive autoantibodies were detected in the sera of 24 of the 235 patients with primary SS and 2 of the 50 controls. Anti‐TRIM38 positivity was significantly associated with the presence of anti‐Ro60, anti‐Ro52, anti‐La, rheumatoid factor, and hypergammaglobulinemia. Clinically, anti‐TRIM38 was associated with significantly higher ocular surface staining scores, lower Schirmer's test scores, and minor labial salivary gland biopsy focus scores of ≥3.0. Anti‐TRIM38 antibodies mainly recognized the cortactin‐binding protein 2 (CortBP‐2; amino acids 128–238) and the B30.2/SPRY (amino acids 268–465) domains on TRIM38. Affinity‐purified antibodies to TRIM38–CortBP‐2 and TRIM38–B30.2/SPRY domains reacted with TRIM21.Conclusion: Our data demonstrate that anti‐TRIM38 specificity arising in a subset of patients with primary SS is associated with increased severity of the disease.
- 26 March 2013
- Published by SAGE Publications in Journal of Dental Research
- Vol. 92 (5) , 444-449
Type I Interferon Receptor Deficiency Prevents Murine Sjögren’s Syndrome
In Sjögren’s Syndrome (SS), inherent glandular defects, autoimmunity, and mononuclear cell infiltration within the salivary glands cause reduced salivation leading to xerostomia. Excessive production of type I interferons (IFN), triggered by environmental and genetic factors, is considered pathogenic in this disorder. However, whether type I IFN production is causative or an outcome of the disease process is not known. To address this question, we introduced a deficiency of interferon alpha receptor 1 ( Ifnar1) into B6. Aec1Aec2 mice, which are known to have the genetic loci necessary for developing a SS-like disorder. This new mouse strain, B6. Aec1Aec2Ifnar1-/-, lacking type I IFN-mediated signaling, was characterized for pilocarpine-induced salivation, the presence of serum autoantibodies, sialoadenitis, and dacryoadenitis. Compared with the B6. Aec1Aec2Ifnar1+/+ (wild-type) mice, the B6. Aec1Aec2Ifnar1-/- (knockout) mice had significantly lower mononuclear cell infiltration in the salivary and lacrimal glands. The knockout mice were completely protected from salivary gland dysfunction. Surprisingly, they had a robust autoantibody response comparable with that of the wild-type mice. These findings demonstrate that, in the absence of type I IFN-mediated signaling, systemic autoantibody responses can be dissociated from glandular pathology. Our study suggests that, in genetically susceptible individuals, the type I IFN pathway can instigate certain features of SS.
- 26 March 2013
- Published by SAGE Publications in Journal of Dental Research
- Vol. 92 (5) , 444-449
Type I Interferon Receptor Deficiency Prevents Murine Sjögren’s Syndrome
In Sjögren’s Syndrome (SS), inherent glandular defects, autoimmunity, and mononuclear cell infiltration within the salivary glands cause reduced salivation leading to xerostomia. Excessive production of type I interferons (IFN), triggered by environmental and genetic factors, is considered pathogenic in this disorder. However, whether type I IFN production is causative or an outcome of the disease process is not known. To address this question, we introduced a deficiency of interferon alpha receptor 1 ( Ifnar1) into B6. Aec1Aec2 mice, which are known to have the genetic loci necessary for developing a SS-like disorder. This new mouse strain, B6. Aec1Aec2Ifnar1-/-, lacking type I IFN-mediated signaling, was characterized for pilocarpine-induced salivation, the presence of serum autoantibodies, sialoadenitis, and dacryoadenitis. Compared with the B6. Aec1Aec2Ifnar1+/+ (wild-type) mice, the B6. Aec1Aec2Ifnar1-/- (knockout) mice had significantly lower mononuclear cell infiltration in the salivary and lacrimal glands. The knockout mice were completely protected from salivary gland dysfunction. Surprisingly, they had a robust autoantibody response comparable with that of the wild-type mice. These findings demonstrate that, in the absence of type I IFN-mediated signaling, systemic autoantibody responses can be dissociated from glandular pathology. Our study suggests that, in genetically susceptible individuals, the type I IFN pathway can instigate certain features of SS.